However, it has been demonstrated that in mouse melanoma models, the variation in treatment efficiency with timing of administration aligns with increased tumour-associated macrophages and rhythmic expression of the Pdcd1 gene Pdcd1 (encoding PD-1) [20]. This evidence concerns the gene PDCD1 and neoplasm.